Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 136Lenalidomide 83daratumumab 75Bortezomib 65Cyclophosphamide 49pomalidomide 46carfilzomib 45Calcium Dobesilate 42Specimen Handling 35Biopsy 32Magnetic Resonance Spectroscopy 29belantamab mafodotin 26fludarabine 23isatuximab 21talquetamab 19dexamethasone acetate 19dexamethasone 21-phosphate 19auricularum 19iberdomide 18Melphalan 17fludarabine phosphate 14elotuzumab 12selinexor 10X-Rays 10tocilizumab 9Nivolumab 8trametinib 7Whole-Body Irradiation 7Sirolimus 7Crizotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
efineptakin alfa × Plasma cell × 90 days × Clear all
NCT07200089 2026-04-07

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Washington University School of Medicine

Phase 1 Not yet recruiting
52 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡